drugset / Trial / NCT01943422
Safety and Efficacy Study of Vemurafenib and High-dose Interferon Alfa-2b in Melanoma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a dose-seeking and efficacy study of combined BRAF Inhibitor Vemurafenib and High-dose Interferon alfa-2b for therapy of advanced melanoma.
Timeline
- Start
- 2013-10
- Primary completion
- 2016-11
- Completion
- 2016-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | High-dose Interferon alfa-2b | Unknown | 10 unknown | Intravenous |
| Subject | High-dose Interferon alfa-2b | Unknown | 15 unknown | Intravenous |
| Subject | High-dose Interferon alfa-2b | Unknown | 20 unknown | Intravenous |
| Subject | Vemurafenib | Small molecule | 960 mg | Oral |